Hypoxia and Inflammation as a Consequence of β-Fibril Accumulation: A Perspective View for New Potential Therapeutic Targets
Table 2
Common clinical features of amyloidosic diseases.
Clinical features
Description and mechanisms
References
Familial
Mutations of the involved protein, strictly influencing misfolding and conformational instability, such as transthyretin in familial amyloidosic polyneuropathy
Conditions presenting abnormal/toxic production and posttransductional misfolding of culprit proteins, such as plasmocytoma (light chains) or chronic inflammatory diseases (SAA) or haemodialysis-related amyloidosis (β2-microglobulin)
Organ-limited amyloidosis in which β-fibrils and polymers may became resident, almost stably, in the extracellular space around the cells producing the misfolded protein (see text)
Bulk production and secretion of culprit protein in the extracellular space; protein entering the vessel lumen may be evidenced in blood plasma by a typical electrophoretic peak; accumulation in the extracellular space of distant tissues around the organism (liver, kidney, myocardium, lungs, brain, etc.), such as primary systemic amyloidosis (Ig light chains) and senile systemic amyloidosis (nonmutated transthyretin)
The rate of amyloid accumulation depends not only on the rate of synthesis and on insensitivity to the extracellular proteases but also on the early start and duration length of disease.
A low-degree inflammation is constantly present in a patient bearing amyloidosis. Its intensity level is determined by the strength of the activation mechanisms (see text) and by the nature of the involved protein.
There are a few specific studies demonstrating that the space accumulating the amyloid substance is actually hypoxic. However, an accurate evaluation of the distance between the vessels and the peripheral parenchymal cells shows that frequently this is larger than 200 μm, which is the diffusion limit of gas such as oxygen and carbon dioxide.